Michael Naso, PhD

Michael Naso has worked for more than 30 years in pharma and biotech organizations toward the discover and movement into early development innovative therapeutics including antibodies, bispecific antibodies, cell and gene therapies.  Michael contributed to the successful approval and marketing of REMICADE, SIMPONI, STELARA, TREMFYA, as well as numerous preclinical programs at Centocor and Janssen.  Most recently, he helped found Century Therapeutics and built the research organization there that brought the first ever multiply precision engineered, iPSC derived cell therapy into the clinic for lymphoma and autoimmunity.  In this role, he worked with the management team to set company strategy, interact with investors and board members, and make vital contributions to financial projections. Michael has extensive expertise in protein engineering, including regulatory submissions and patent filings.  He has also served as an expert witness in legal matters.